Sun Pharma March-quarter net profit rises 57 percent

Thu May 29, 2014 6:56pm IST

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May 29, 2014. REUTERS/Danish Siddiqui

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May 29, 2014.

Credit: Reuters/Danish Siddiqui

Related Topics

Stocks

   

REUTERS - Sun Pharmaceutical Industries Ltd (SUN.NS), India's third-largest drugmaker by revenue, on Thursday reported a 57 percent jump in fourth-quarter net profit, slightly above expectations, helped by higher sales in the United States, its largest market.

The company, which is in the process of acquiring loss-making rival Ranbaxy Laboratories Ltd (RANB.NS), posted a net profit of 15.87 billion rupees ($269.55 million) in January-March, compared with 10.12 billion rupees a year earlier. Analysts on average expected 15.74 billion rupees, according to Thomson Reuters data.

Sales in January-March rose 32 percent to 40.44 billion rupees. The company also said it expects a 13 to 15 percent growth in sales in full-year 2015.

Sun Pharma, a bellwether in India's $15-billion pharmaceutical industry, agreed in April to buy Ranbaxy from Japan's Daiichi Sankyo Ltd (4568.T) for $3.2 billion, creating the world's fifth-largest maker of generic drugs.

The drugmaker, however, faces an uphill task in turning around Ranbaxy's business and fixing manufacturing quality issues that have resulted in several Ranbaxy plants being barred from exporting to the United States.

Sun Pharma is also working towards resolving quality control issues that got its Karkhadi, India, plant banned by the U.S. Food and Drug Administration in March.

The company's shares, which are up 4 percent so far this year, ended 0.43 percent higher, while the Nifty was down 1.3 percent.

($1 = 58.8750 rupees)

(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Pricing Controls

REUTERS SHOWCASE

India-China Relations

India-China Relations

India says to defend China border after standoff ahead of Xi visit.  Full Article 

Importing Iron Ore

Importing Iron Ore

As mining curbs bite, India offers market to glut-hit iron ore.  Full Article 

Drug Approval

Drug Approval

Epirus, Ranbaxy win India approval for arthritis drug copy.  Full Article 

Rajan Speaks

Rajan Speaks

RBI chief Rajan says limiting reliance on foreign debt.  Full Article 

Debt & Equity Deal

Debt & Equity Deal

KKR to lend $175 million to GMR Infrastructure - source.  Full Article 

Preparing for IPO

Preparing for IPO

Alibaba boosts IPO as demand strengthens.  Full Article 

India-Vietnam Ties

India-Vietnam Ties

India tightens Vietnam defence, oil ties ahead of China Xi's visit.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage